Coveram Dosage/Direction for Use

Posology: Oral route.
One tablet per day as a single dose, preferably to be taken in the morning and before a meal.
The fixed dose combination is not suitable for initial therapy.
If a change of posology is required, the dose of Coveram could be modified or individual titration with free combination may be considered.
Special populations: Renal impairment and elderly (see "Precautions" and "Pharmacology: Pharmacokinetics under Actions").
Elimination of perindoprilat is decreased in the elderly and in patients with renal failure. Therefore, the usual medical follow-up will include frequent monitoring of creatinine and potassium.
Coveram can be administered in patients with Clcr ≥60 mL/min, and is not suitable for patients with Clcr <60 mL/min. In these patients, an individual dose titration with the monocomponents is recommended.
Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment.
Hepatic impairment: See "Precautions" and "Pharmacology: Pharmacokinetics under Actions".
Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see "Precautions" and "Pharmacology: Pharmacokinetics under Actions"). To find the optimal starting dose and maintenance dose of patients with hepatic impairment, the patients should be individually titrated using the free combination of amlodipine and perindopril. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.
Paediatric population: Coveram should not be used in children and adolescents (less than 18 years) as the efficacy and tolerability of perindopril and amlodipine, alone or in combination, have not been established in children and adolescents.